[1] Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on
Streptococcus pneumoniae bacteraemia in a South African population. AIDS. 1998;12:2177-84.
[2] Theodoratou E, McAllister DA, Reed C, Adeloye DO, Rudan I, Muhe LM, et al. Global,
regional, and national estimates of pneumonia burden in HIV-infected children in 2010:
a meta-analysis and modelling study. The Lancet Infectious Diseases. 2014;14:1250-8.
[3] Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency
virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African
children. The Pediatric infectious disease journal. 2000;19:1141-7.
[4] Von Mollendorf C, Von Gottberg A, Tempia S, Meiring S, De Gouveia L, Quan V, et
al. Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed
but uninfected infants aged< 1 year in South Africa, 2009–2013. Clinical Infectious
Diseases. 2015;60:1346-56.
[5] von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et
al. Effects of vaccination on invasive pneumococcal disease in South Africa. The New
England journal of medicine. 2014;371:1889-99.
[6] Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, et al.
Persistent high burden of invasive pneumococcal disease in South African HIV-infected
adults in the era of an antiretroviral treatment program. PloS one. 2011;6:e27929.
[7] Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness
of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease
in the elderly in England and Wales. Vaccine. 2012;30:6802-8.
[8] Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive
pneumococcal disease among infants before and after introduction of pneumococcal conjugate
vaccine. Jama. 2006;295:1668-74.
[9] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline
in invasive pneumococcal disease after the introduction of protein–polysaccharide
conjugate vaccine. The New England journal of medicine. 2003;348:1737-46.
[10] Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained
reductions in invasive pneumococcal disease in the era of conjugate vaccine. The Journal
of infectious diseases. 2010;201:32-41.
[11] Latifi-Navid H, Latifi-Navid S, Mostafaiy B, Jamalkandi SA, Ahmadi A. Pneumococcal
Disease and the Effectiveness of the PPV23 Vaccine in Adults: A Two-Stage Bayesian
Meta-Analysis of Observational and RCT Reports. Sci Rep. 2018;8:11051.
[12] O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate
and polysaccharide vaccines: is hyporesponsiveness an issue? The Lancet Infectious
Diseases. 2007;7:597-606.
[13] Borrow R, Heath PT, Siegrist C-A. Use of pneumococcal polysaccharide vaccine
in children: what is the evidence? Current opinion in infectious diseases. 2012;25:292-303.
[14] Warnatz K. Dissecting CXCR5+ T cell populations–on the quest for a better understanding
of B cell help during T dependent antibody responses. European journal of immunology.
2006;36:1662-4.
[15] Madhi SA, Klugman KP, Kuwanda L, Cutland C, Käyhty H, Adrian P. Quantitative
and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected
and HIV-uninfected children 5 years after vaccination. The Journal of infectious diseases.
2009;199:1168-76.
[16] Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific
changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction:
a pooled analysis of multiple surveillance sites. PLoS medicine. 2013;10:e1001517.
[17] Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal
vaccination. The Lancet. 2011;378:1962-73.
[18] Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, et al.
Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal
disease in South African children: a case-control study. The Lancet Global health.
2017;5:e359-e69.
[19] Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V, et al.
Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal
disease in HIV-infected and -uninfected children in south africa: a matched case-control
study. Clinical Infectious Diseases. 2014;59:808-18.
[20] Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of
a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
The New England journal of medicine. 2003;349:1341-8.
[21] Jallow S, Madhi SA. Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed,
uninfected children. Expert Review of Vaccines. 2017;16:453-65.
[22] Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, et al. The
evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal
disease. The Lancet infectious diseases. 2008;8:67-80.
[23] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
[24] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
[25] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment
of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology.
2010;25:603-5.
[26] Halloran ME, Haber M, Longini Jr IM, Struchiner CJ. Direct and indirect effects
in vaccine efficacy and effectiveness. American Journal of Epidemiology. 1991;133:323-31.
[27] Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clinical infectious
diseases. 2011;52:911-6.
[28] Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect
effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease:
a systematic review and meta-analysis. The Lancet Global health. 2017;5:e51-e9.
[29] Sigurdsson S, Erlendsdóttir H, Quirk SJ, Kristjánsson J, Hauksson K, Andrésdóttir
BDI, et al. Pneumococcal vaccination: Direct and herd effect on carriage of vaccine
types and antibiotic resistance in Icelandic children. Vaccine. 2017;35:5242-8.
[30] Smith C, Ding L, Gorbach P, Franco E, Kahn J. Who’s not protected in the herd?
Factors associated with vaccine-type HPV in unvaccinated women. Journal of Pediatric
and Adolescent Gynecology. 2017.
[31] Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus
pneumoniae causing invasive disease in children in the post-PCV era: A systematic
review and meta-analysis. PloS one. 2017;12:e0177113.
[32] Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence
of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent
conjugate vaccine. Clinical Infectious Diseases. 2008;46:174-82.
[33] Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, et al.
Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in
an American Indian population at high risk for disease. Clinical infectious diseases.
2010;50:1238-46.
[34] Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist A-C, et al.
Risk factors for invasive pneumococcal disease in children in the era of conjugate
vaccine use. Pediatrics. 2010:peds. 2009-150.
[35] Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al.
Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children
with high levels of 7-valent pneumococcal conjugate vaccine coverage. Jama. 2007;297:1784-92.
[36] Bamford A, Kelleher P, Lyall H, Haston M, Zancolli M, Goldblatt D, et al. Serological
response to 13-valent pneumococcal conjugate vaccine in children and adolescents with
perinatally acquired HIV infection. AIDS (London, England). 2014;28:2033.
[37] King Jr JC, Borkowsky W, Mahidhara N, Madore D, Shapiro ED, Rutstein RM, et al.
Group-specific antibody levels surrounding invasive pneumococcal illness in children
infected with human immunodeficiency virus. The Journal of infectious diseases. 2000;181:1817-21.
[38] Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, et al. Long-term
immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human
immunodeficient virus infected and non-infected children in the absence of a booster
dose of vaccine. Vaccine. 2007;25:2451-7.
[39] Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al.
Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate
vaccine in infants and toddlers. The Pediatric infectious disease journal. 2006;25:312-9.
[40] van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, et al.
Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal
pneumococcal carriage in children: a randomized controlled trial. Jama. 2009;302:159-67.
[41] Vestrheim DF, Løvoll Ø, Aaberge IS, Caugant DA, Høiby EA, Bakke H, et al. Effectiveness
of a 2+ 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal
disease among children in Norway. Vaccine. 2008;26:3277-81.
[42] Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype
replacement 4 years after seven-valent pneumococcal conjugate vaccination in England
and Wales: an observational cohort study. The Lancet infectious diseases. 2011;11:760-8.
[43] Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new
serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127-31.
[44] Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal
conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected
children. Clinical Infectious Diseases. 2005;40:1511-8.
[45] Avni T, Mansur N, Leibovici L, Paul M. PCR using blood for diagnosis of invasive
pneumococcal disease: systematic review and meta-analysis. Journal of clinical microbiology.
2010;48:489-96.
[46] Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination
of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal
pneumonia. Clinical Infectious Diseases. 2004;39:165-9.
[47] Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate
vaccine in HIV-infected individuals. Human vaccines & immunotherapeutics. 2012;8:161-73.
[48] Madhi SA, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Quantitative and
qualitative antibody response to pneumococcal conjugate vaccine among African human
immunodeficiency virus-infected and uninfected children. The Pediatric infectious
disease journal. 2005;24:410-6.
[49] Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Immunogenicity
and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine
in symptomatic HIV-1 infected children. Vaccine. 2005;23:5289-93.
[50] von Mollendorf C, Cohen C, de Gouveia L, Naidoo N, Meiring S, Quan V, et al.
Risk factors for invasive pneumococcal disease among children less than 5 years of
age in a high HIV prevalence setting, South Africa, 2010 to 2012. The Pediatric infectious
disease journal. 2015;34:27-34.
[51] Steenhoff AP, Wood SM, Rutstein RM, Wahl A, McGowan KL, Shah SS. Invasive pneumococcal
disease among human immunodeficiency virus-infected children, 1989-2006. The Pediatric
infectious disease journal. 2008;27:886-91.
[52] Nzenze SA, Madhi SA, Shiri T, Klugman KP, de Gouveia L, Moore DP, et al. Imputing
the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine
Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal
Pneumococcal Colonization. American Journal of Epidemiology. 2017;186:435-44.